Scribe Enters CRISPR-Based Collaboration with Biogen
Biosimilar Approvals Stall During COVID-19 Pandemic, But the Pipeline Grows
U.S. Biosimilar Launches Accelerate with Five Launches in Q4 2019 and early 2020
Time to Rethink “Consisting Essentially of” as a Claim Limitation
FDA Approves Four Biosimilars During Summer 2019 While Europe is on Vacation
House Democrats Seek to Remove Biologics Exclusivity Period From USMCA
What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework
Responding to Growing Criticisms, PTAB Expands Discretion to Deny Institution
